Introduction

OHSS is a serious complication of ovulation induction, occurring in 1–10% of in vitro fertilization patients (Rizk and Aboulghar, 1991; Brinsden et al., 1995). This iatrogenic condition has a spectrum of clinical and laboratory manifestations ranging from mild to severe, even life-threatening conditions (Rizk et al., 1990). Among the serious manifestations of OHSS are ascites and pleural effusion (Rizk and Smitz, 1992). The exact mechanism causing fluid collection in these spaces is still not completely understood. Vascular endothelial growth factor has emerged as one of the factors most likely involved in the pathophysiology of OHSS (Geva and Jaffe, 2000; Rizk and Aboulghar, 2010). Vascular endothelial growth factor is an angiogenic cytokine that is a potent stimulator of the vascular endothelium and appears to play an integral role in follicular growth, corpus luteum function and ovarian angiogenesis (Rizk et al., 1997). Vascular endothelial growth factor causes increased capillary permeability with its sequelae of ascites and possible pleural effusion (Rizk et al., 1997; Gomez et al., 2002). Human chorionic gonadotrophin is thought to play a crucial role in the development of
OHSS (Rizk et al., 1997; Wang et al., 2002; Delbaere et al., 1997). Two distinct forms of severe OHSS have been described: early and late forms (Papanikolaou et al., 2005; Mathur et al., 2000). Early OHSS is caused by the administration of exogenous human chorionic gonadotrophin (hCG) and it starts before the 10th day after oocyte retrieval, while the late form is the result of endogenous human chorionic gonadotrophin release in the event of pregnancy, and it starts after the 10th day following oocyte aspiration (Papanikolaou et al., 2005; Mathur et al., 2000; Rizk, 2006, 2009).

Several strategies to prevent OHSS have been described in the literature. Such strategies included the use of low dose gonadotropins and frequent monitoring during controlled ovarian stimulation, cycle cancellation, coasting, freeze all embryos and the use of gonadotropin releasing hormone (GnRH) agonist as an oocyte trigger in GnRH antagonist cycles (Rizk et al., 1991; Donoso and Devroey, 2013; Griesinger, 2010). The use of antagonist in the luteal phase with total freeze of embryos to prevent severe OHSS has also been suggested (Lainas et al., 2012). Such strategies should be used especially in patients at high risk for developing severe OHSS, including those who are young, have low body weight, have polycystic ovary syndrome, those who experience high estradiol levels, rapidly increasing estradiol levels, high number of follicles during controlled ovarian stimulation and those with high number of oocytes retrieved (Rizk and Aboulghar, 1999; Delvigne, 2009). Dopamine agonists have been proposed for the prevention of OHSS in women at high risk. However, the study by Álvarez et al. (2007) suggested that it was only effective in reducing the incidence of moderate OHSS, but not in its severe form (Alvarez et al., 2007). Low-dose aspirin therapy and doxycycline have also been suggested to inhibit angiogenesis (Fainaru et al., 2009). Devroey et al. (2011) believes that the concept of an OHSS-Free Clinic has become a reality. The authors suggest that this approach should include pituitary down-regulation using a GnRH antagonist, ovulation triggering with a GnRH agonist and vitrification of oocytes or embryos (Devroey et al., 2011).

Severe and critical forms of OHSS are associated with significant ascites (Golan et al., 1989; Rizk et al., 2010). Ascites results in an increased abdominal pressure compromising venous return, cardiac output and renal perfusion (Navot et al., 1992; Rizk et al., 2010). Paracentesis is frequently needed, as prompt drainage of fluid produces a significant clinical and biochemical improvement, including spontaneous diuresis and hastening the resolution process (Rizk et al., 2010; Aboulghar et al., 1990; Padilla et al., 1990). In critical cases of OHSS, multiple paracenteses may be required to relieve symptoms and avoid serious sequelae of hemoconcentration, hypotension, decreased renal perfusion and severe respiratory compromise. Instead of multiple interventions, the placement of a catheter temporarily for a few days will permit complete drainage through one procedure (Rizk and Aboulghar, 1999).

Pigtail catheters have been used for drainage in various clinical situations. In a previous study we described the use of percutaneous placement of a pigtail catheter for drainage of ascites caused by severe/critical OHSS (Abuzeid et al., 2003). In this study we established the efficacy and safety of pigtail catheter drainage in the management of severe/critical OHSS in patients who underwent in vitro fertilization and embryo transfer at our centre between 1999 and 2001 on both inpatient and outpatient basis. The aim of the current study was to evaluate the role of the pigtail catheter drainage in outpatient management of patients with early onset severe OHSS.

Materials and Methods

This is a retrospective study that included all patients who underwent in vitro fertilization and developed severe or critical OHSS by the Golan Classification (Golan et al., 1989) in the period between 2004 and 2009. Approval for this study was obtained from the local Institutional Review Board. All patients underwent an ultrasound evaluation which documented the presence of severe ascites and bilateral ovarian enlargement. Urine output, weight and abdominal girth were monitored. All patients presented with shortness of breath, marked abdominal distension, nausea, weight gain and lower abdominal pain. Thirteen patients complained of vomiting, and 3 patients reported decreased urine output (less than 720 cc per 24 hours) and had haemoglobin ≥ 15 g/dL. All 33 patients were offered treatment using pigtail catheter insertion as an alternative to trans-vaginal paracentesis. Blood studies including a complete blood count, creatinine, electrolytes, serum albumin and total protein, and coagulation panel were ordered prior to the procedure. Chest x-ray was ordered whenever pleural effusion was suspected clinically. All 33 patients were rehydrated with intravenous crystalloid solutions (0.9% normal saline). This was started before the procedure and continued afterwards. Care was taken to give the patient the same amount of fluid as the amount that was drained from the peritoneal cavity.

All pigtail catheter placements were performed in the operating room at our surgical centre. The
catheter (6-0 French, 2.0 mm, Boston Scientific, Quincy, MA, USA) was introduced utilizing a non-disposable metal gamete intra-fallopian treatment (GIFT) trocar and cannula (Embryon GIFT catheter, IVF ONLINE, Gilford, CT, USA) which was introduced into the largest accessible ascitic fluid pocket in the upper outer quadrant of the abdominal wall under local anaesthesia and trans-abdominal ultrasound guidance. The trocar was then removed and a glide wire (Boston Scientific Corp., Watertown, MA, USA) was threaded through the GIFT canula. The canula was removed with care so as to keep the glide wire in the peritoneal cavity. The pigtail catheter was guided into the peritoneal cavity by the wire after removal of the stylet of the pigtail catheter. The glide wire was removed. The catheter was anchored to the skin using 2-0 silk suture and it was supported by gauze, which was covered by a Tegaderm. The catheter was connected to a three-way stop cock which was connected to a drainage bag. Initial amount of drained fluid was calculated and subsequently the patients were trained to drain 1000 cc per day (500 cc in the morning and 500 cc in the evening). One liter normal saline and 500 cc of 6% hydroxyethyl starch solution (Hespan) was administered to the patient on the same day of pigtail catheter placement.

Any patient with critical OHSS according to the Golan classification, or those in whom the presenting symptoms and signs did not completely subside after drainage of ascitic fluid and IV fluid replacement, were admitted to the hospital for observation and further management. All other patients were sent home. Once there was minimal or no drainage from the catheter, the patient returned to the office for removal of the catheter. The patients were encouraged to drink plenty of fluids and to increase their protein intake. A nurse performed regular follow-up phone calls on a daily basis. All patients kept a diary for body weight, abdominal girth, and urine output before and after the procedure. These findings were reported to the nurse. Patients were seen in the office as needed for evaluation and hydration with normal saline.

Results

Demographic data including mean age (years), duration of infertility (years), BMI (kg/m2) and aetiology of infertility are illustrated in Table I. Ovarian stimulation data including number of treatment days, total dose of recombinant follicle stimulating hormone, hormone serum levels, endometrial thickness, number of follicles and number of patients receiving only 5000 IU of human chorionic gonadotrophin is illustrated in Table II.

| Table I. — Demographic Data |
|-----------------------------|
| Total no. of patients   | 33 |
| Mean age (years)        | 31 ± 3 |
| Duration of infertility (years) | 2.4 ± 1.8 |
| BMI (kg/m²)            | 27 ± 6 |
| Percent of patients with primary infertility | 59% |
| Percent of patients with PCOS | 58% |

Values are expressed as mean ± standard deviation.

| Table II. — Ovarian stimulation data |
|----------------------------------|
| No. of treatment days         | 9.5 ± 1.9 |
| Total dose of rFSH            | 1522.6 ± 525.2 IU |
| Total dose of hMG             | 510.5 ± 565.7 IU |
| Total dose of gonadotropin     | 2033.1 ± 692.2 IU |
| Serum E2 levels on day of HCG  | 2643.9 ± 1311.6 pg/ml |
| Serum P4 levels on day of HCG  | 0.8 ± 0.3 ng/ml |
| Serum LH levels on day of HCG  | 2.0 ± 2.2 mIU/ml |
| Serum FSH levels on day of HCG | 12.3 ± 4.7 mIU/ml |
| Endometrial thickness on day of HCG | 10.1 ± 2.1 mm |
| No of follicles < 14 mm on day of HCG | 17.4 ± 8.2 |
| No of follicles > 14 mm on day of HCG | 11.1 ± 6.7 |
| Total no. of follicles on day of HCG | 27.5 ± 10.7 |
| Serum E2 levels on first day of coasting | 1552.7 ± 2210.5 pg/ml |
| Serum E2 levels on second day of coasting | 1515.3 ± 2578.0 pg/ml |
| No of patients (%) receiving only 5000 IU of HCG | 15 (45.5%) |

Values are expressed as mean ± standard deviation: rFSH = recombinant FSH; hMG = human menopausal gonadotropins; HCG = human chorionic gonadotropin; E2 = estradiol
Pigtail catheter details are shown in Table III. Our data include the number of patients requiring early versus late placement of pigtail catheter, mean amount of ascitic fluid drained immediately after pigtail placement, number of days of pigtail catheter drainage and the number of days between oocyte retrieval and the onset of severe OHSS symptoms requiring pigtail placement. Table III also illustrates the number of patients who underwent coasting, number of patients who received prophylactic Hespan on day of egg retrieval.

| Table III. — Hyperstimulation and Pigtail catheter data |
|--------------------------------------------------------|
|                                                                                                   |
| No of patients (%) requiring early placement of pigtail catheter                                  |
| No. of patients (%) requiring late placement of pigtail catheter                                  |
| Mean amount of ascitic fluid drained immediately after pigtail placement (cc)                      |
| No. of days of pigtail catheter drainage                                                           |
| No. of days of between oocyte retrieval and onset of severe OHSS symptoms requiring pigtail placement |
| Early onset                                                                                         |
| Late onset                                                                                          |
| No. of patients (%) who underwent coasting                                                          |
| No of patients (%) who received prophylactic Hespan (one liter) on day of egg retrieval             |
|                                                                                                   |
| 3 (9.1%)                                                                                              |
| 30 (90.9%)                                                                                             |
| 2085 ± 1018                                                                                           |
| 7.8 ± 5.3 days                                                                                         |
| 4.3 ± 0.6 days                                                                                         |
| 14 ± 4 days                                                                                             |
| 26 (78.8%)                                                                                             |
| 26 (78.8%)                                                                                             |

Values are expressed as mean ± standard deviation

Discussion

OHSS has several classifications (Golan et al., 1989; Navot et al., 1992; Rizk and Aboulghar, 1999), but perhaps the most accepted classification of OHSS is the one described by Golan et al as mild, moderate and severe (Golan et al., 1989). However, clinicians should be aware that OHSS is a dynamic condition and moderate OHSS may progress to severe OHSS within hours (Rizk and Aboulghar, 1999; Rizk, 2009). Therefore, the practice committee of the American Society for Reproductive Medicine (ASRM) proposed a classification for OHSS of mild, worsening and serious (The Practice Committee of the American Society for Reproductive Medicine, 2008). Recognizing the patients at high-risk, prevention and early recognition are the most important steps in the management of OHSS (Rizk, 2006). However, severe forms of OHSS, especially late onset type that occurs when patients are pregnant, most likely will continue to happen, albeit at much lower rate, unless one reverts to a total freeze of all embryos after the use of GnRH agonist as a trigger shot in a GnRH antagonist cycle (Donoso and Devroey, 2013; Devroey et al., 2011).

Traditional treatment consists mainly of supportive management until spontaneous resolution occurs (Rizk, 1994). Although moderate OHSS does not usually require intervention, outpatient monitoring is essential to identify progression to a severe form (Rizk, 2006). Patients with moderate OHSS can be managed on an outpatient basis by adequate hydration and close daily monitoring of weight gain and abdominal girth to detect progression to severe OHSS, and to provide intervention, if required (Rizk, 2010). Patients presenting with severe forms of OHSS are usually managed on inpatient basis and most patients with critical OHSS are admitted to intensive care units for aggressive supportive measures to avoid maternal morbidity and mortality (The Practice Committee of the American Society for Reproductive Medicine, 2008).

Correction of hypovolemia, electrolyte imbalance and hypoalbuminemia are the basic principles during the treatment of severe OHSS (Rizk, 1994, 2006; Myrianthefs et al., 2000). In addition, Navot et al. (1992) suggested that paracentesis is the single most important treatment modality in life-threatening OHSS not controlled by medical therapy. Paracentesis and removal of ascites result in relieving the pressure on the inferior vena cava and improvement in venous return, cardiac output and renal perfusion (Padilla et al., 1990).
Therefore, prompt drainage of fluid produces significant clinical and biochemical improvement, including spontaneous diuresis and hastening the resolution process (Abuzeid et al., 2003; The Practice Committee of the American Society for Reproductive Medicine, 2008). It is also possible that removal of ascites decreases the amount of VEGF and its effects on vascular permeability. Therefore ultrasound guided drainage of the ascitic fluid should be performed in severe cases of OHSS with respiratory distress, oliguria or severe abdominal pain (Padilla et al., 1990). This can be done either trans-vaginaIly (AbouIghar et al., 1990) or trans-abdominally (Padilla et al., 1990). However, recurrence of ascites is common in severe cases of OHSS. Placement of a pigtail catheter has been proposed by some investigators to allow drainage of ascitic fluid whenever it accumulates without the need for further surgical procedures (Abuzeid et al., 2003). In a previous study we reported the use of percutaneous pigtail catheter for drainage of ascites in severe OHSS as an alternative to repeated paracentesis (Abuzeid et al., 2003). Catheter placement was performed under local anaesthesia and under trans-abdominal ultrasound guidance. This procedure is relatively simple and requires a short period of time as compared to the time needed to gradually aspirate any fluid accumulation transvaginaIly. It also avoids the need for multiple needle paracentesis if recurrence occurred. Immediate relief of symptoms and signs of severe OHSS after pigtail catheter insertion was an important finding. In addition, the ease by which any accumulated ascitic fluid was drained resulted in a faster resolution of OHSS (Abuzeid et al., 2003). Despite the fact that no prophylactic antibiotics were administered, no infection was reported (Abuzeid et al., 2003).

In that study the first 13 patients were admitted to the hospital for a few days. They were discharged home with the pigtail catheter in place and managed on an outpatient basis until OHSS subsided; thereafter the catheter was removed. The last 13 patients were managed on an outpatient basis without any problem (Abuzeid MI, et al., 2003). Our previous study confirmed the safety and effectiveness of the pigtail catheter for the management of severe OHSS. Therefore, we embarked on the current study to evaluate the role of pigtail catheter drainage in outpatient management of patients with severe OHSS syndrome.

In the current study we demonstrated that patients who were diagnosed very early with severe OHSS can be managed safely and effectively on outpatient basis using pigtail catheter drainage, IV fluid replacement and careful monitoring. Although all 33 patients presented with shortness of breath, marked abdominal distension, nausea, weight gain and lower abdominal pain, and 13 of them complained of vomiting, (all are criteria for hospital admission according to the practice committee of the American Society for Reproductive Medicine on OHSS), 30 patients were sent home as their presenting symptoms were relieved. Early diagnosis and intervention resulted in rapid elimination of the symptoms of severe OHSS and normalization of vital signs, which allow us to manage the patients on outpatient basis. The pigtail catheter placements were performed without complications and patients were discharged home after a few hours of observation.

The patients who needed hospital admission were those with associated severe pleural effusion requiring thoracentesis. Another patient was admitted to the hospital for 1 day for work up for chest pain and possible diagnosis of pulmonary embolism. Once pulmonary embolism was ruled out, she was discharged home with a pigtail catheter in place and she was managed on outpatient basis. No intensive care unit admissions were required in any of these patients.

Outpatient management of OHSS has no place in those who fail to have complete resolutions of their symptoms, or those with severe hyperproteinuria or electrolyte imbalance. Certainly it has no place in patients with critical OHSS such as those with severe pleural effusion, diminished urine output, severe hemoconcentration and those at increased risk of thromboembolic risks (Rizk, 2010). It is imperative to stress that such a protocol can only be used in patients who are motivated, reliable and have the necessary support at home to allow them to return to the clinic or go to the emergency room if the need arises. It also requires dedicated in vitro fertilization nurses to educate and follow up the patient on a daily basis.

Contrary to other reports that state that access to intravenous albumin is a critical part of outpatient management for severe OHSS, we did not use any albumin replacement (Lincoln et al., 2002). The reason behind the use of intravenous albumin is to increase intravascular oncotic pressure, thereby curtailing the exodus of free water from the intravascular space. In our study we used Hespan instead of albumin, as some investigators have shown that it is beneficial in reducing the incidence of severe OHSS (Youssef et al., 2011). By increasing the intravascular oncotic pressure, Hespan helps in decreasing the incidence of ascites and symptoms of severe OHSS. Hespan is also less expensive than albumin. However, Hespan is a category C drug with adverse effects in animals. In addition, the majority
of our patients had late onset OHSS as a result of pregnancy. Therefore the use of Hespan should be discontinued once pregnancy is confirmed. Hespan should be used with caution in patients with late onset OHSS only when benefits outweigh risks. It is a fact that outpatient management of early severe OHSS is a common practice among infertility specialists after trans-vaginal aspiration of ascitic fluid and IV fluid hydration. Outpatient management by repeated abdominal or trans-vaginal paracentesis has been reported to be safe, effective and cost effective (Lincoln et al., 2002; Shrivastav et al., 1994; Fluker et al., 2000; Csokmay et al., 2010). Shrivastav et al. (1994) were the first to suggest that day care management in patients with severe OHSS with abdominal paracentesis and IV hydration was simple, safe and effective compared with traditional treatment with in-patient hospitalization and supportive measures. In addition, Lincoln et al. (2002) concluded that the need for hospitalization for hyperstimulated patients can be minimized by outpatient management of severe OHSS with trans-vaginal culdocentesis and rehydration with crystalloids and albumin. Furthermore Fluker et al. (2000) advocated in a pilot study an active management strategy for moderate OHSS, which involved early paracentesis designed to minimize the progression from moderate to severe OHSS, instead of late paracentesis aimed at speeding up recovery in severely ill patients. Csokmay et al. (2010) concluded that early outpatient paracentesis for moderate to severe OHSS is the most cost effective management plan when compared with traditional conservative inpatient therapy. Smith et al. (2009) reported a large series of patients with severe OHSS in whom the vast majority were successfully managed as outpatients with use of aggressive trans-vaginal paracentesis (Smith et al., 2009).

Despite the findings in our study it is important to emphasize that OHSS remains a serious disorder with the potential for rapid deterioration, requiring hospitalization and intensive treatment of a critically ill patient. The life-threatening complications of OHSS are secondary to thromboembolism or compromised pulmonary or cardiovascular function and multi-organ failure. There have been isolated reports of women dying from the complications associated with OHSS. The mortality rate related to OHSS is very low and was estimated by Brinsden et al. (1995) to occur in 1/400,000 to 1/500,000 cycles of OHSS. More recently, reports regarding maternal mortality rates due to OHSS in the Netherlands and United Kingdom demonstrate an incidence of approximately 3 deaths per 100,000 in IVF cycles (Braat et al., 2006; Lewis, 2007). Eleven lethal complications of assisted reproductive technology have been documented and summarized by Braat et al. (2006). Several investigators reported sporadic fatality as a result of OHSS due to adult respiratory distress syndrome, massive pulmonary oedema, myocardial infarction, and carotid artery occlusion resulting in cerebral infarction.

In this study we describe a modified technique of what interventional radiologists usually use for pigtail catheter placement. We observed that in the obese patients the metal introducer provided in the pigtail catheter kit is difficult to use; instead we used the non disposable gamete intra-fallopian treatment trocar and cannula to facilitate the introduction of the catheter through the abdominal wall of such patients. We subsequently adopted its use in all cases. We found that the technique is easy to learn by the practicing gynaecologist. This technique helps to manage the patients in the office without the need for sending her to the hospital for an interventional radiologist to place the catheter.

Our study has limitations as a result of its design being retrospective in nature. However, the patients in this study were identified from our in vitro fertilization database; the study included every patient who developed severe/critical OHSS. In addition, the lack of a control group that was managed without pigtail catheter placement limits the conclusions that can be drawn from our study.

In summary, drainage of ascitic fluid in patients with severe/critical OHSS is an important step in the management of this condition (Rizk, 2010). The placement of a pigtail catheter resulted in a safe and effective outpatient management of the majority of patients with severe OHSS. However, outpatient management of this potentially fatal condition requires clear understanding that rapid deterioration may occur, which may necessitate hospitalization and intensive treatment of a critically ill patient (Rizk, 2006, 2010). Patients with critical OHSS and those with persistence of symptoms of severe OHSS despite insertion of a pigtail catheter and drainage of ascitic fluid should be admitted to the hospital for inpatient management.

Acknowledgements

The authors would like to thank Cheryl Anderson for her assistance in the preparation of this paper.

References

Aboulghar MA, Mansour RT, Serour GI et al. Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril. 1990;53:933–5

Abuzeid MI, Nassar Z, Massaad Z et al. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod. 2003;18:370-3.
Álvarez C, Martí-Bonmatí L, Novella-Maestre E et al. Dopamine agonist cabergoline reduces hemococoncentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007;92:2931–7.

Braat D, Bernardus R, Gerris J. Anonymous reports of lethal cases of ovarian hyperstimulation syndrome. In Gerris J, Olivennes F and Delvigne A (eds.). Ovarian hyperstimulation syndrome. UK: Informa Healthcare, 2006, pp. 59–70.

Brinsden PR, Wada I, Tan SL et al. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol.1995;102:767-72.

Cookman JM, Yauger BJ, Henne MB et al. Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “taper early and often” versus hospitalization. Fertil Steril. 2010;93:167-73.

Delbaere A, Bergmann PJM, Gervy-Decoster C et al. Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation. Fertil Steril. 1997;67:1038-45.

Delvigne A. Symposium: Update on prediction and management of OHSS. Epidemiology of OHSS. Reprod BioMed Online. 2007;15:11-13.

Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by Segmentation of IVF treatment. Hum Reprod. 2011;26:2593-7.

Donoso P, Devroey P. Low tolerance for complications. Fertil Steril. 2013;100:299-301.

Fainaru O, Hornstein MD, Folkman J. Doxycycline inhibits vascular leakage and prevents ovarian hyperstimulation syndrome in a murine model. Fertil Steril. 2009; 92:1701-5.

Flucker MR, Copeland JE, Yuzpe AA. An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:821-4.

Geva E, Jaffe RB. Role of vascular endothelial growth factor in ovarian physiology and Pathology. Fertil Steril. 2000; 74:429-38.

Golan A, Ron-el R, Herman A et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989; 44:430-40.

Gomez R, Simon C, Remohi J et al. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinol. 2002;143:439-48.

Griesinger G. Ovarian Hyperstimulation Syndrome Prevention Strategies: Use of GnRHi Releasing Hormone Antagonists. Semin Reprod Med. 2010;28:493-9.

Lainas GT, Kolhbianakis EM, Stfontouris IA et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Bio Endocrinol. 2012;10:69. http://www.rbej.com/content/10/1/69

Lewis G. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2003–2005. The seventh report on confidential enquiries into maternal deaths in the United Kingdom. London: CEMACH, 2007.

Lincoln SR, Opsahl MS, Blauer KL et al. Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transcervical culdoscopesis and intravenous albumin minimizes hospitalization. J Assist Reprod Genet. 2002;19:159-63.

Mathur RS, Akande AV, Keya SD et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901-7.

Myrianthefs P, Ladasik C, Lappas V et al. Ovarian hyperstimulation syndrome (OHSS): diagnosis and management. J Intensive Care Med. 2000;26:631-4.

Navot D, Bergh PA, Lafer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249-61.

Padilla SL, Zamaria S, Baramki TA et al. Abdominal paracentesis for the ovarian hyperstimulation syndrome with severe pulmonary compromise. Fertil Steril. 1990;53:365-7.

Papanikolaou EG, Tournaye H, Verpoest W et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod Update. 2005;20:636-41.

Rizk B. Ovarian hyperstimulation syndrome. In: Studd J, ed. Progress in Obstetrics and Gynecology, vol. 11. Edinburgh: Churchill Livingstone;1994:311-49.

Rizk B. Coasting for the prevention of critical OHSS: an American perspective. In: Gerris J, Olivennes F, Delvigne A, eds. Ovarian Hyperstimulation Syndrome. London: Taylor and Francis;2006:247-67.

Rizk B. Genetics of ovarian hyperstimulation syndrome. Reprod Biomed Online. 2009;19:14-27.

Rizk B. Complications of ovulation induction. II. Ovarian hyperstimulation syndrome. In: Dickey RP, Brinsden PR, Pyrzak R, eds. Manual of Intratineine Insemination and Ovulation Induction. Cambridge: Cambridge University Press; 2010:152-60.

Rizk B, Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod. 1991;6:1082-7.

Rizk B, Aboulghar M. Ovarian hyperstimulation syndrome. In: Rizk B, Aboulghar M, eds. Ovarian Stimulation. Cambridge: Cambridge University Press; 2010:38-39.

Rizk B, Smitz J. Ovarian hyperstimulation syndrome after superovulation for IVF and related procedures. Hum Reprod. 1992;7:320-7.

Rizk B, Meagher S, Fisher AM. Ovarian hyperstimulation syndrome and cerebrovascular accidents. Hum Reprod. 1990;5:697-8.

Rizk B, Aboulghar MA, Mansour RT et al. Severe ovarian hyperstimulation syndrome: analytical study of twenty-one cases. Proceedings of the VII World Procreations, Paris. Hum Reprod. 1991;6:368-9.

Rizk B, Aboulghar MA, Smitz J et al. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997;3:255-66.

Rizk B, Aboulghar MA. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden P, ed. A Textbook of In-vitro Fertilization and Assisted Reproduction. 2nd edn. Camforth: Parthenon;1999:131-55.

Rizk B, Rizk CB, Nawar MG et al. Ultrasonography in the prediction and management of ovarian hyperstimulation syndrome. In: Rizk B, ed. Ultrasonography in Reproductive Medicine and Infertility. Cambridge: Cambridge University Press;2010:299-312.

Shrivastav P, Nadkarni P, Craft I. Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity. Hum Reprod. 1994;9:812-4.

Smith LP, Hacker MR, Alper MM. Patients with severe ovarian Hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis. Fertil Steril. 2009;92:1953-9.

The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome Fertil Steril. 2008;90:Suppl S188-93.

Wang TH, Horng SG, Chang CL et al. Chorionic Gonadotropin-induced Ovarian Hyperstimulation Syndrome Is Associated with Up-Regulation of Vascular Endothelial Growth Factor. J Clin Endocrinol Metab. 2002;87:3300–8.

Yousif MAPM, Al-Inany HG, Evers J LH et al. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews. 2011;(2):CD001302.